Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework.

PubWeight™: 1.00‹?› | Rank: Top 15%

🔗 View Article (PMC 2980751)

Published in Biophys J on November 17, 2010

Authors

M L Bellows1, M S Taylor, P A Cole, L Shen, R F Siliciano, H K Fung, C A Floudas

Author Affiliations

1: Department of Chemical and Biological Engineering, Princeton University, Princeton, NJ, USA.

Articles citing this

De novo peptide design and experimental validation of histone methyltransferase inhibitors. PLoS One (2014) 1.42

De novo peptide design with C3a receptor agonist and antagonist activities: theoretical predictions and experimental validation. J Med Chem (2012) 1.04

Protein folding and de novo protein design for biotechnological applications. Trends Biotechnol (2013) 1.02

Molecular dynamics in drug design: new generations of compstatin analogs. Chem Biol Drug Des (2012) 0.90

Molecular recognition of CCR5 by an HIV-1 gp120 V3 loop. PLoS One (2014) 0.88

Forcefield_PTM: Ab Initio Charge and AMBER Forcefield Parameters for Frequently Occurring Post-Translational Modifications. J Chem Theory Comput (2013) 0.86

An evolution-based approach to De Novo protein design and case study on Mycobacterium tuberculosis. PLoS Comput Biol (2013) 0.85

Molecular recognition of CXCR4 by a dual tropic HIV-1 gp120 V3 loop. Biophys J (2013) 0.85

Forcefield_NCAA: ab initio charge parameters to aid in the discovery and design of therapeutic proteins and peptides with unnatural amino acids and their application to complement inhibitors of the compstatin family. ACS Synth Biol (2014) 0.85

Protein WISDOM: a workbench for in silico de novo design of biomolecules. J Vis Exp (2013) 0.84

Elucidating a key component of cancer metastasis: CXCL12 (SDF-1α) binding to CXCR4. J Chem Inf Model (2014) 0.84

Derivation of ligands for the complement C3a receptor from the C-terminus of C5a. Eur J Pharmacol (2014) 0.83

Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment. J Control Release (2015) 0.83

Novel compstatin family peptides inhibit complement activation by drusen-like deposits in human retinal pigmented epithelial cell cultures. Exp Eye Res (2013) 0.83

Computational methods for de novo protein design and its applications to the human immunodeficiency virus 1, purine nucleoside phosphorylase, ubiquitin specific protease 7, and histone demethylases. Curr Drug Targets (2010) 0.81

Systematic optimization model and algorithm for binding sequence selection in computational enzyme design. Protein Sci (2013) 0.79

Elucidating a key anti-HIV-1 and cancer-associated axis: the structure of CCL5 (Rantes) in complex with CCR5. Sci Rep (2014) 0.79

De novo design and experimental characterization of ultrashort self-associating peptides. PLoS Comput Biol (2014) 0.79

New compstatin peptides containing N-terminal extensions and non-natural amino acids exhibit potent complement inhibition and improved solubility characteristics. J Med Chem (2014) 0.76

Computational Design of Hypothetical New Peptides Based on a Cyclotide Scaffold as HIV gp120 Inhibitor. PLoS One (2015) 0.75

Articles cited by this

Core structure of gp41 from the HIV envelope glycoprotein. Cell (1997) 16.18

Torsion angle dynamics for NMR structure calculation with the new program DYANA. J Mol Biol (1997) 15.40

Protein structure prediction using Rosetta. Methods Enzymol (2004) 12.05

HIV entry and its inhibition. Cell (1998) 9.42

Automated NMR structure calculation with CYANA. Methods Mol Biol (2004) 9.31

Protein-protein docking with simultaneous optimization of rigid-body displacement and side-chain conformations. J Mol Biol (2003) 8.35

Native protein sequences are close to optimal for their structures. Proc Natl Acad Sci U S A (2000) 7.99

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother (2005) 7.42

Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci U S A (1998) 4.34

The dead-end elimination theorem and its use in protein side-chain positioning. Nature (1992) 4.11

Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell (1999) 3.29

Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med (2008) 3.28

Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J Virol (2004) 3.13

A large scale test of computational protein design: folding and stability of nine completely redesigned globular proteins. J Mol Biol (2003) 3.08

Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol (2006) 2.91

Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure (2008) 2.74

Application of a self-consistent mean field theory to predict protein side-chains conformation and estimate their conformational entropy. J Mol Biol (1994) 2.74

Computational design of protein-protein interactions. Curr Opin Chem Biol (2004) 2.39

De novo determination of protein backbone structure from residual dipolar couplings using Rosetta. J Am Chem Soc (2002) 2.12

Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc Natl Acad Sci U S A (2007) 2.02

Short constrained peptides that inhibit HIV-1 entry. Proc Natl Acad Sci U S A (2002) 1.77

Potent D-peptide inhibitors of HIV-1 entry. Proc Natl Acad Sci U S A (2007) 1.76

Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem (2008) 1.74

A novel ensemble-based scoring and search algorithm for protein redesign and its application to modify the substrate specificity of the gramicidin synthetase a phenylalanine adenylation enzyme. J Comput Biol (2005) 1.66

HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. Curr Pharm Des (2007) 1.66

Protein-protein docking predictions for the CAPRI experiment. Proteins (2003) 1.60

Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc Natl Acad Sci U S A (2009) 1.55

CAPRI rounds 3-5 reveal promising successes and future challenges for RosettaDock. Proteins (2005) 1.54

De novo protein design. II. Plasticity in sequence space. J Mol Biol (1999) 1.53

ASTRO-FOLD: a combinatorial and global optimization framework for Ab initio prediction of three-dimensional structures of proteins from the amino acid sequence. Biophys J (2003) 1.47

Computational methods in protein structure prediction. Biotechnol Bioeng (2007) 1.39

De novo protein design. I. In search of stability and specificity. J Mol Biol (1999) 1.37

Dead-end elimination with backbone flexibility. Bioinformatics (2007) 1.30

Integrated computational and experimental approach for lead optimization and design of compstatin variants with improved activity. J Am Chem Soc (2003) 1.28

Exploring folding free energy landscapes using computational protein design. Curr Opin Struct Biol (2004) 1.27

2.1 and 1.8 A average C(alpha) RMSD structure predictions on two small proteins, HP-36 and s15. J Am Chem Soc (2001) 1.25

Coupling backbone flexibility and amino acid sequence selection in protein design. Protein Sci (1997) 1.25

Recapitulation of protein family divergence using flexible backbone protein design. J Mol Biol (2005) 1.23

A novel high resolution Calpha--Calpha distance dependent force field based on a high quality decoy set. Proteins (2006) 1.20

Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41. J Med Chem (2008) 1.20

SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide. Antimicrob Agents Chemother (2008) 1.15

Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide. Int J Biochem Cell Biol (2008) 1.12

Distance dependent centroid to centroid force fields using high resolution decoys. Proteins (2008) 1.10

New compstatin variants through two de novo protein design frameworks. Biophys J (2010) 1.08

Biclustering via optimal re-ordering of data matrices in systems biology: rigorous methods and comparative studies. BMC Bioinformatics (2008) 1.07

Toward full-sequence de novo protein design with flexible templates for human beta-defensin-2. Biophys J (2007) 1.03

Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors. J Biol Chem (2008) 0.97

Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. J Biol Chem (2008) 0.96

Design and synthesis of human immunodeficiency virus entry inhibitors: sulfonamide as an isostere for the alpha-ketoamide group. J Med Chem (2007) 0.95

NMR second site screening for structure determination of ligands bound in the hydrophobic pocket of HIV-1 gp41. J Am Chem Soc (2009) 0.93

A new pairwise folding potential based on improved decoy generation and side-chain packing. Proteins (2004) 0.92

Combinatorial protein design. Curr Opin Struct Biol (2002) 0.92

N- and C-domains of HIV-1 gp41: mutation, structure and functions. Immunol Lett (2001) 0.92

Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. J Med Virol (2004) 0.92

Comparative docking study of anibamine as the first natural product CCR5 antagonist in CCR5 homology models. J Chem Inf Model (2009) 0.84

Inhibition of HIV-1 infection by synthetic peptides derived CCR5 fragments. Biochem Biophys Res Commun (2006) 0.81

Manipulation of electrostatic and saccharide linker interactions in the design of efficient glycopolypeptide-based cholera toxin inhibitors. Macromol Biosci (2010) 0.80

Computer-based design of novel HIV-1 entry inhibitors: neomycin conjugated to arginine peptides at two specific sites. J Mol Model (2008) 0.78

Articles by these authors

(truncated to the top 100)

The transcriptional landscape of the mammalian genome. Science (2005) 37.63

Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature (2002) 28.79

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10

Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature (1997) 15.49

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 12.68

Sonic hedgehog, a member of a family of putative signaling molecules, is implicated in the regulation of CNS polarity. Cell (1993) 7.41

Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet (2000) 7.16

In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med (1995) 6.26

Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques (2003) 5.49

SOME MORPHOLOGICAL AND BIOLOGICAL CHARACTERS OF THE SPIRILLA (VIBRIO FETUS, N. SP.) ASSOCIATED WITH DISEASE OF THE FETAL MEMBRANES IN CATTLE. J Exp Med (1919) 4.96

Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A (2009) 4.58

Secretion of proinflammatory cytokines by epithelial cells in response to Chlamydia infection suggests a central role for epithelial cells in chlamydial pathogenesis. J Clin Invest (1997) 4.51

Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol (2000) 4.46

A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature (1988) 4.15

Expressed protein ligation: a general method for protein engineering. Proc Natl Acad Sci U S A (1998) 4.01

Defects in enteric innervation and kidney development in mice lacking GDNF. Nature (1996) 3.82

Antibody-dependent cell-mediated cytotoxicity due to a "null" lymphoid cell. Nat New Biol (1973) 3.68

HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. JAMA (2001) 3.41

Structure of a DNA-bound Ultrabithorax-Extradenticle homeodomain complex. Nature (1999) 3.06

HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Mol Cell (2000) 2.68

Endocytosis of endogenously synthesized HIV-1 envelope protein. Mechanism and role in processing for association with class II MHC. J Immunol (1995) 2.62

Sertoli cell signaling by Desert hedgehog regulates the male germline. Curr Biol (1996) 2.59

Characterization of the antibody-dependent cytotoxic cell. A non-phagocytic monocyte? Clin Exp Immunol (1973) 2.53

Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein. Nature (1985) 2.51

Cytotoxicity mediated by human Fc receptors for IgG. Immunol Today (1989) 2.47

Defects in development of the kidney, heart and eye vasculature in mice homozygous for a hypomorphic Notch2 mutation. Development (2001) 2.37

Activator-dependent transcription from chromatin in vitro involving targeted histone acetylation by p300. Mol Cell (2000) 2.25

Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection. J Infect Dis (2000) 2.25

Mechanism-based design of a protein kinase inhibitor. Nat Struct Biol (2001) 2.13

Cloning and sequence analysis of cDNAs encoding two distinct somatostatin precursors found in the endocrine pancreas of anglerfish. Nature (1980) 2.11

Viral dynamics in HIV-1 infection. Cell (1998) 2.08

Proteoglycans are required for maintenance of Wnt-11 expression in the ureter tips. Development (1996) 1.99

Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1. J Virol (2000) 1.95

Phagocytosis mediated by three distinct Fc gamma receptor classes on human leukocytes. J Exp Med (1990) 1.89

Tethered blockers as molecular 'tape measures' for a voltage-gated K+ channel. Nat Struct Biol (2000) 1.89

CpG island methylation in colorectal adenomas. Am J Pathol (2001) 1.88

The human immunodeficiency virus type 1 gag gene encodes an internal ribosome entry site. J Virol (2001) 1.87

A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children. J Clin Invest (2000) 1.81

Human immunodeficiency virus type 1 envelope protein endocytosis mediated by a highly conserved intrinsic internalization signal in the cytoplasmic domain of gp41 is suppressed in the presence of the Pr55gag precursor protein. J Virol (1996) 1.79

Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine. Science (1990) 1.78

Transcriptional coactivator protein p300. Kinetic characterization of its histone acetyltransferase activity. J Biol Chem (2001) 1.77

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol (2013) 1.76

Polymorphonuclear leukocyte function triggered through the high affinity Fc receptor for monomeric IgG. J Immunol (1987) 1.72

Site-specific incorporation of a phosphotyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling. Mol Cell (2001) 1.68

Cytotoxic T lymphocytes do not appear to select for mutations in an immunodominant epitope of simian immunodeficiency virus gag. J Immunol (1992) 1.65

Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology (2010) 1.63

Targeted deletion of MyD88 in intestinal epithelial cells results in compromised antibacterial immunity associated with downregulation of polymeric immunoglobulin receptor, mucin-2, and antibacterial peptides. Mucosal Immunol (2012) 1.62

T cell receptor V beta repertoire in an acute infection of rhesus monkeys with simian immunodeficiency viruses and a chimeric simian-human immunodeficiency virus. J Exp Med (1995) 1.61

Dependence of germinal center B cells on expression of CD21/CD35 for survival. Science (1998) 1.59

Expression cloning of a human Fc receptor for IgA. J Exp Med (1990) 1.59

Enhancing substance abuse treatment with case management. Its impact on employment. J Subst Abuse Treat (1997) 1.54

A rational approach to management of alendronate-related subtrochanteric fractures. J Bone Joint Surg Br (2010) 1.53

The interobserver and intraobserver reliability of the cooney classification of distal radius fractures between experienced orthopaedic surgeons. J Hand Surg Eur Vol (2007) 1.53

Aberrant methylation of the Cyclooxygenase 2 CpG island in colorectal tumors. Cancer Res (2000) 1.53

Postmenopausal squamous atypia: a spectrum including "pseudo-koilocytosis". Mod Pathol (1995) 1.50

Highly specific, membrane-permeant peptide blockers of cGMP-dependent protein kinase Ialpha inhibit NO-induced cerebral dilation. Proc Natl Acad Sci U S A (2000) 1.49

Modulation of human polymorphonuclear leukocyte IgG Fc receptors and Fc receptor-mediated functions by IFN-gamma and glucocorticoids. J Immunol (1988) 1.49

ASTRO-FOLD: a combinatorial and global optimization framework for Ab initio prediction of three-dimensional structures of proteins from the amino acid sequence. Biophys J (2003) 1.47

Chromatin-dependent cooperativity between constitutive and inducible activation domains in CREB. Mol Cell Biol (2001) 1.46

Subpopulations of human peripheral granulocyes and monocytes express receptors for IgA. Proc Natl Acad Sci U S A (1980) 1.44

Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci (1997) 1.44

Role of interaction of CD2 molecules with lymphocyte function-associated antigen 3 in T-cell recognition of nominal antigen. Proc Natl Acad Sci U S A (1990) 1.44

Simian immunodeficiency virus evades a dominant epitope-specific cytotoxic T lymphocyte response through a mutation resulting in the accelerated dissociation of viral peptide and MHC class I. J Immunol (2000) 1.43

Type I (CD64) and type II (CD32) Fc gamma receptor-mediated phagocytosis by human blood dendritic cells. J Immunol (1996) 1.39

Development and evaluation of a real-time PCR assay for detection of Pneumocystis jirovecii DNA in bronchoalveolar lavage fluid of HIV-infected patients. Thorax (2007) 1.39

Peptide and protein phosphorylation by protein tyrosine kinase Csk: insights into specificity and mechanism. Biochemistry (1998) 1.39

p300/CBP-associated factor histone acetyltransferase processing of a peptide substrate. Kinetic analysis of the catalytic mechanism. J Biol Chem (2000) 1.38

Characterization of a conserved T cell epitope in HIV-1 gp41 recognized by vaccine-induced human cytolytic T cells. J Immunol (1991) 1.38

Human helicase gene SKI2W in the HLA class III region exhibits striking structural similarities to the yeast antiviral gene SKI2 and to the human gene KIAA0052: emergence of a new gene family. Nucleic Acids Res (1995) 1.37

Biosynthesis of bacterial glycogen. IV. Activation and inhibition of the adenosine diphosphate glucose pyrophosphorylase of Escherichia coli B. Biochemistry (1966) 1.35

Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. Leukemia (2009) 1.35

Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med (2004) 1.34

Contribution of fibrin stabilization to clot strength. Supplementation of factor XIII-deficient plasma with the purified zymogen. J Clin Invest (1983) 1.32

Direct evidence for the existence of nominal antigen binding sites on T cell surface Ti alpha-beta heterodimers of MHC-restricted T cell clones. Cell (1986) 1.32

Characteristics of the effector cells mediating cytotoxicity against antibody-coated target cells. I. Phagocytic and non-phagocytic effector cell activity against erythrocyte and tumour target cells in a 51Cr release cytotoxicity assay and [125I]IUdR growth inhibition assay. Immunology (1975) 1.32

Tuberculosis treatment effect on T-cell interferon-gamma responses to Mycobacterium tuberculosis-specific antigens. Eur Respir J (2009) 1.31

Evaluating local public health performance at a community level on a statewide basis. J Public Health Manag Pract (1995) 1.30

Whole-exome sequencing and imaging genetics identify functional variants for rate of change in hippocampal volume in mild cognitive impairment. Mol Psychiatry (2013) 1.30

Estradiol selectively regulates innate immune function by polarized human uterine epithelial cells in culture. Mucosal Immunol (2008) 1.30

A soluble, single-chain T-cell receptor fragment endowed with antigen-combining properties. Proc Natl Acad Sci U S A (1991) 1.28

Secretory IgA antibodies synergize with IgG in promoting ADCC by human polymorphonuclear cells, monocytes, and lymphocytes. Cell Immunol (1981) 1.26

The major metabolite of equilin, 4-hydroxyequilin, autoxidizes to an o-quinone which isomerizes to the potent cytotoxin 4-hydroxyequilenin-o-quinone. Chem Res Toxicol (1999) 1.26

Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. J Infect Dis (1995) 1.26

Room-temperature ferromagnetism in carbon-doped ZnO. Phys Rev Lett (2007) 1.26

Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. Clin Exp Immunol (2011) 1.25

Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J Exp Med (1997) 1.25

A novel method for detection and ex vivo expansion of HIV type 1-specific cytolytic T lymphocytes. AIDS Res Hum Retroviruses (1994) 1.25

Genome-wide association with MRI atrophy measures as a quantitative trait locus for Alzheimer's disease. Mol Psychiatry (2010) 1.24

An enzymatic basis for secretor status and blood group substance specificity in humans. Proc Natl Acad Sci U S A (1968) 1.24

A class of specific cytotoxic cells demonstrated in vitro by arming with antigen-antibody complexes. Nat New Biol (1973) 1.24

Cytofluorographic analysis of receptors for IgA on human polymorphonuclear cells and monocytes and the correlation of receptor expression with phagocytosis. Mol Immunol (1983) 1.24

Vaccination of rhesus monkeys with synthetic peptide in a fusogenic proteoliposome elicits simian immunodeficiency virus-specific CD8+ cytotoxic T lymphocytes. J Exp Med (1992) 1.23

Combination of hsa-miR-375 and hsa-miR-142-5p as a predictor for recurrence risk in gastric cancer patients following surgical resection. Ann Oncol (2011) 1.22

Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. J Infect Dis (1999) 1.21

Aberrant DNA methylation associated with silencing BNIP3 gene expression in haematopoietic tumours. Br J Cancer (2005) 1.21

Kinetic analysis of the catalytic mechanism of serotonin N-acetyltransferase (EC 2.3.1.87). J Biol Chem (1998) 1.20

Immune biology of macaque lymphocyte populations during mycobacterial infection. Clin Exp Immunol (2003) 1.20

A novel high resolution Calpha--Calpha distance dependent force field based on a high quality decoy set. Proteins (2006) 1.20

GDNF acutely modulates excitability and A-type K(+) channels in midbrain dopaminergic neurons. Nat Neurosci (2001) 1.20

Characterization of a new four-chain coiled-coil: influence of chain length on stability. Protein Sci (1995) 1.19